Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Cancer Therapies02:49

Cancer Therapies

9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

6.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.7K
Drug Therapy01:28

Drug Therapy

223
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
223
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Reply to the letter "About sorafenib in castration-resistant prostate cancer" by G. Colloca, F. Checcaglini and A. Venturino.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.

Investigational new drugs·2018
Same author

Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.

Breast cancer research and treatment·2017
Same author

PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same journal

PDLIM2 acts as a central regulator of ubiquitination, immune signaling, and mitochondrial metabolism in lung cancer suppression (Review).

International journal of oncology·2026
Same journal

Understanding the epigenetic regulation of lactylation and aberrant lactate metabolism in cancer: From mechanisms to therapeutic strategies (Review).

International journal of oncology·2026
Same journal

Stress‑induced catecholamines attenuate sorafenib efficacy by inhibiting ferroptosis in β2‑adrenergic receptor positive renal cell carcinoma.

International journal of oncology·2026
Same journal

[Expression of Concern] TIP60 governs the auto‑ubiquitination of UHRF1 through USP7 dissociation from the UHRF1/USP7 complex.

International journal of oncology·2026
Same journal

Radiotherapy resistance in glioblastoma: Mechanistic insights and novel therapeutic approaches (Review).

International journal of oncology·2026
Same journal

[Retracted] Honokiol, a phytochemical from <i>Magnolia spp.</i>, inhibits breast cancer cell migration by targeting nitric oxide and cyclooxygenase‑2.

International journal of oncology·2026
See all related articles

Related Experiment Video

Updated: Jan 3, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.0K

Sequential alpha-interferon and tamoxifen.

L Seymour1, W Bezwoda

  • 1UNIV WITWATERSRAND,DEPT MED,DIV CLIN HAEMATOL & MED ONCOL,ZA-2050 WITWATERSRAND,SOUTH AFRICA.

International Journal of Oncology
|May 3, 2011
PubMed
Summary
This summary is machine-generated.

Sequential administration of tamoxifen (TMX) and alpha-interferon (IFN) showed complementary effects on breast cancer cells. This combination therapy demonstrated significant antiproliferative activity and modulated key biomarkers, suggesting potential for breast cancer treatment.

More Related Videos

Identification Of Erythromyeloid Progenitors And Their Progeny In The Mouse Embryo By Flow Cytometry
08:59

Identification Of Erythromyeloid Progenitors And Their Progeny In The Mouse Embryo By Flow Cytometry

Published on: July 17, 2017

13.4K
Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.1K

Related Experiment Videos

Last Updated: Jan 3, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.0K
Identification Of Erythromyeloid Progenitors And Their Progeny In The Mouse Embryo By Flow Cytometry
08:59

Identification Of Erythromyeloid Progenitors And Their Progeny In The Mouse Embryo By Flow Cytometry

Published on: July 17, 2017

13.4K
Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.1K

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Tamoxifen (TMX) and alpha-interferon (IFN) possess complementary biological activities relevant to breast cancer.
  • Hormone-responsive breast cancer cell lines, like MCF-7, serve as valuable models for studying therapeutic interventions.

Purpose of the Study:

  • To investigate the biologic effects of sequential administration of tamoxifen and alpha-interferon.
  • To evaluate the impact of this combination on breast cancer cell proliferation and specific molecular markers.

Main Methods:

  • Utilized the hormone-responsive MCF-7 breast cancer cell line.
  • Administered tamoxifen and alpha-interferon sequentially.
  • Assessed antiproliferative effects and changes in expression of Estrogen Receptor (ER), TGF-beta, c-erbB-2, P24, and Ki67.

Main Results:

  • Alpha-interferon exhibited significant antiproliferative effects and increased ER and TGF-beta expression.
  • The combination therapy demonstrated at least additive antiproliferative effects.
  • Combined treatment modulated the expression of ER, TGF-beta, c-erbB-2, P24, and Ki67.

Conclusions:

  • Alpha-interferon modulates tamoxifen-induced biological effects in breast cancer cells.
  • Sequential administration of alpha-interferon and tamoxifen offers a potentially significant approach for modulating breast cancer endpoints.
  • Further research is warranted to explore the clinical implications of this combined therapeutic strategy.